Tag: taxanes
Taxanes: A class of drugs that inhibit cancer cell division (mitosis). Taxanes interfere with the functioning of microtubules (which help move chromosomes during mitosis). Examples include Taxol (paclitaxel) and Taxotere (docetaxel).Articles
- How to optimize your breast cancer diet
- Latest research concerning side effects of chemotherapy
- Latest research concerning triple negative breast cancer prognosis
- Latest research on factors influencing Taxol (paclitaxel) effectiveness
- What should breast cancer patients eat during Taxol (paclitaxel) chemotherapy?
News
- Apigenin increases effectiveness of Taxol chemotherapy
- Bisphosphonates for treating osteoporosis may significantly reduce risk of breast cancer
- Brassica compound DIM inhibits breast cancer cell growth synergistically with Taxotere
- Fish oil component can increase survival time for Stage IV breast cancer patients
- Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer
- Modern chemotherapy reduces breast cancer death by about a third compared to no chemotherapy
- Muscle and joint pain are common during taxane chemotherapy for breast cancer
- Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
- Possible toxic side effects of chemotherapy
- Predictors of failure to respond to neoadjuvant chemotherapy
- Response to neoadjuvant chemotherapy depends on dosage and tumor type
- Resveratrol increases effectiveness of Taxotere (docetaxel) and Adriamycin (doxorubicin)
- Survival times for metastatic breast cancer have been improving
- The beta blocker propranolol increases the effectiveness of Taxol
Foods
Studies
- 3, 3'-diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC)
- Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells
- Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
- Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo
- Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model
- Cytotoxicity of curcumin combined with docetaxel in MCF7 breast tumor cells implicates the glutathione cycle and an antioxidant response: a metabolomics investigation
- d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis
- Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation
- Differential response from neoadjuvant chemotherapy across breast cancer subtypes
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
- Exogenous supplementation with [omega]-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
- Fifteen-year trends in metastatic breast cancer survival in Greece
- Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer
- Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
- Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
- Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline-based neoadjuvant and adjuvant chemotherapy
- Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer
- Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy
- Outcomes of inflammatory versus noninflammatory T4 breast cancers in the age of taxanes and trastuzumab
- Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
- Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
- Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer
- Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
- Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40)
- Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro
- Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer